Dr. Janet M. Leeds, PhD, of Portola Pharmaceuticals, Inc., Discusses Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients With Acute Major Bleeding, from the International Society on Thrombosis and Haemostasis Meeting in Berlin, July, 2017

свернуть